[go: up one dir, main page]

WO2011140208A3 - Methods and compositions for diagnosing and treating autoimmune disorders - Google Patents

Methods and compositions for diagnosing and treating autoimmune disorders Download PDF

Info

Publication number
WO2011140208A3
WO2011140208A3 PCT/US2011/035174 US2011035174W WO2011140208A3 WO 2011140208 A3 WO2011140208 A3 WO 2011140208A3 US 2011035174 W US2011035174 W US 2011035174W WO 2011140208 A3 WO2011140208 A3 WO 2011140208A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosing
compositions
autoimmune disorders
treating autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/035174
Other languages
French (fr)
Other versions
WO2011140208A2 (en
Inventor
Eric Wendell Triplett
Adriana Giongo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of WO2011140208A2 publication Critical patent/WO2011140208A2/en
Publication of WO2011140208A3 publication Critical patent/WO2011140208A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)

Abstract

Embodiments of the present disclosure provide for methods and kits for diagnosing autoimmune conditions, a predisposition for an autoimmune condition, and/or for diagnosing autoimmunity leading to type 1 diabetes (T1 D), TID, and/or a predisposition for TID, and type 1 diabetes; methods and compositions for treatment of autoimmunity and/or type 1 diabetes; probiotic compositions, and the like.
PCT/US2011/035174 2010-05-04 2011-05-04 Methods and compositions for diagnosing and treating autoimmune disorders Ceased WO2011140208A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33100010P 2010-05-04 2010-05-04
US61/331,000 2010-05-04

Publications (2)

Publication Number Publication Date
WO2011140208A2 WO2011140208A2 (en) 2011-11-10
WO2011140208A3 true WO2011140208A3 (en) 2012-04-19

Family

ID=44904452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035174 Ceased WO2011140208A2 (en) 2010-05-04 2011-05-04 Methods and compositions for diagnosing and treating autoimmune disorders

Country Status (1)

Country Link
WO (1) WO2011140208A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104363769B (en) * 2012-02-28 2016-08-24 康奈尔大学 Probiotic composition and method
CN104540962B (en) * 2012-08-01 2017-09-19 深圳华大基因研究院 Diabetes biomarker and its application
US20150211053A1 (en) * 2012-08-01 2015-07-30 Bgi-Shenzhen Biomarkers for diabetes and usages thereof
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
EP3679798B1 (en) 2015-02-03 2021-11-17 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating arthritis
AU2016248063A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
CN106389478B (en) * 2015-07-31 2019-12-24 广州知易生物科技有限公司 Application of bacteroides fragilis in treatment and/or prevention of obesity or diabetes
EP3130680A1 (en) * 2015-08-11 2017-02-15 Universitat de Girona Method for the detection, follow up and/or classification of intestinal diseases
WO2017115001A1 (en) * 2015-12-31 2017-07-06 Servicio Andaluz De Salud Method for the identification of individuals susceptible to diabetes
ITUA20164448A1 (en) * 2016-06-16 2017-12-16 Ospedale Pediatrico Bambino Gesù Metagenomic method for in vitro diagnosis of intestinal dysbiosis.
KR102225939B1 (en) * 2018-04-19 2021-03-10 주식회사 고바이오랩 Composition for preventing or treating immunometabolic diseases comprising Bacteroides vulgates
CN112680500A (en) * 2020-12-30 2021-04-20 深圳市第二人民医院(深圳市转化医学研究院) Reagent and biomarker for detecting type 1 diabetes and application of reagent and biomarker

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076696A2 (en) * 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
US20100048595A1 (en) * 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048595A1 (en) * 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
WO2008076696A2 (en) * 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROESCH L. FW ET AL.: "Culture-independent identification of gut bacteria corre lated with the onset of diabetes in a rat model.", THE ISME JOURNAL., vol. 3, 2009, pages 536 - 548 *
YADAV H. ET AL.: "Antidiabetic effect of probiotic dahi containing Lactobacill us acidophilus and Lactobacillus casei in high fructose fed rats.", NUTRITION., vol. 23, 2007, pages 62 - 68 *

Also Published As

Publication number Publication date
WO2011140208A2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2011140208A3 (en) Methods and compositions for diagnosing and treating autoimmune disorders
WO2011031786A3 (en) Compositions and methods for diagnosing autism spectrum disorders
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2008097277A3 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
MX2010005282A (en) Humanized antibodies against tl1a.
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2012076553A3 (en) Biomarkers and parameters for hypertensive disorders of pregnancy
WO2009092752A3 (en) Polyolefins having isotactic structural elements, method for producing the same and use thereof
WO2011083996A3 (en) Primers for diagnosing ankylosing spondylitis, and method for diagnosing ankylosing spondylitis using the same
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
WO2008011433A3 (en) Styrenated terpene resin as well as methods of making and using the same
WO2009120801A3 (en) Ikki inhibitor therapies and screening methods, and related ikki diagnostics
WO2016089732A3 (en) Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
PL2131693T3 (en) Fixing system
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
MX2012001999A (en) Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes.
WO2011147034A8 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof
WO2009103061A3 (en) Methods and compositions for identifying, diagnosing, and treating neuroblastoma
WO2012078618A3 (en) Predicting and treating diabetic complications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11778252

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11778252

Country of ref document: EP

Kind code of ref document: A2